201 related articles for article (PubMed ID: 29989208)
21. EPHA3 as a novel therapeutic target in the hematological malignancies.
Keane N; Freeman C; Swords R; Giles FJ
Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
[TBL] [Abstract][Full Text] [Related]
22. Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.
Nelson KN; Peiris MN; Meyer AN; Siari A; Donoghue DJ
Trends Mol Med; 2017 Jan; 23(1):59-79. PubMed ID: 27988109
[TBL] [Abstract][Full Text] [Related]
23. The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention.
Menck K; Heinrichs S; Baden C; Bleckmann A
Cells; 2021 Jan; 10(1):. PubMed ID: 33445713
[TBL] [Abstract][Full Text] [Related]
24. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
25. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.
Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grandér D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Österborg A
Leuk Lymphoma; 2013 Apr; 54(4):843-50. PubMed ID: 22988987
[TBL] [Abstract][Full Text] [Related]
26. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
27. Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?
Brinkmann K; Kashkar H
Cell Death Dis; 2014 Mar; 5(3):e1098. PubMed ID: 24603326
[TBL] [Abstract][Full Text] [Related]
28. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Koehrer S; Burger JA
Clin Adv Hematol Oncol; 2016 Jan; 14(1):55-65. PubMed ID: 27057669
[TBL] [Abstract][Full Text] [Related]
29. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
Jabbour E; Ottmann OG; Deininger M; Hochhaus A
Haematologica; 2014 Jan; 99(1):7-18. PubMed ID: 24425689
[TBL] [Abstract][Full Text] [Related]
30. Ror2 as a therapeutic target in cancer.
Debebe Z; Rathmell WK
Pharmacol Ther; 2015 Jun; 150():143-8. PubMed ID: 25614331
[TBL] [Abstract][Full Text] [Related]
31. Secreted Wnt antagonists in leukemia: A road yet to be paved.
Pehlivan M; Çalışkan C; Yüce Z; Sercan HO
Leuk Res; 2018 Jun; 69():24-30. PubMed ID: 29625321
[TBL] [Abstract][Full Text] [Related]
32. Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy.
Shabani M; Naseri J; Shokri F
Expert Opin Ther Targets; 2015 Jul; 19(7):941-55. PubMed ID: 25835638
[TBL] [Abstract][Full Text] [Related]
33. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M
Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227
[TBL] [Abstract][Full Text] [Related]
34. Targeting Casein Kinase 1 (CK1) in Hematological Cancers.
Janovská P; Normant E; Miskin H; Bryja V
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261128
[TBL] [Abstract][Full Text] [Related]
35. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
Sankhala K; Giles FJ
Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
[TBL] [Abstract][Full Text] [Related]
36. Diverse regulation of mammary epithelial growth and branching morphogenesis through noncanonical Wnt signaling.
Kessenbrock K; Smith P; Steenbeek SC; Pervolarakis N; Kumar R; Minami Y; Goga A; Hinck L; Werb Z
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3121-3126. PubMed ID: 28270600
[TBL] [Abstract][Full Text] [Related]
37. Receptor Tyrosine Kinases ror1/2 and ryk Are Co-expressed with Multiple Wnt Signaling Components During Early Development of Sea Urchin Embryos.
Ka C; Gautam S; Marshall SR; Tice LP; Martinez-Bartolome M; Fenner JL; Range RC
Biol Bull; 2021 Oct; 241(2):140-157. PubMed ID: 34706206
[TBL] [Abstract][Full Text] [Related]
38. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.
Li M; Chen L; Qu Y; Sui F; Yang Q; Ji M; Shi B; Chen M; Hou P
Oncotarget; 2017 May; 8(22):36319-36330. PubMed ID: 28422736
[TBL] [Abstract][Full Text] [Related]
39. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
40. Wnt5a suppresses osteoblastic differentiation of human periodontal ligament stem cell-like cells via Ror2/JNK signaling.
Hasegawa D; Wada N; Yoshida S; Mitarai H; Arima M; Tomokiyo A; Hamano S; Sugii H; Maeda H
J Cell Physiol; 2018 Feb; 233(2):1752-1762. PubMed ID: 28681925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
